HER2 Support Group Forums - View Single Post - Oral Bondronat Shows Equal Efficacy and Superior Tolerability with Zometa

01-03-2006, 02:30 PM

Bondronat was the subject of an article in a UK paper (Daily Express 3rd Jan 05 page 35), with positive comment from a sufferer with bone mets.

Bondronat is being trailed against radiation in the UK by Cancer Research UK, and there is apparently information on their web site info@cancer.org.uk

I apologise if this has been posted before.

I attach some links from a google search.

RB

http://qualitycounts.com/drugs/chemo...andronate.html

http://www.docguide.com/news/content...25703D0053DBE0

http://www.roche.com/med-cor-2003-07-28

http://www.docguide.com/news/content...2570AB00688815

ABSTRACT

Oral Bondronat Shows Equal Efficacy and Superior Tolerability in First Head-to-Head Comparison with Zometa for Treatment of Metastatic Bone Disease in Cancer Patients

BASEL, SWITZERLAND -- October 31, 2005 -- Data announced today at the European Cancer Conference (ECCO) in Paris, shows Roche's oral Bondronat(R) (ibandronate) results in fewer adverse events than another commonly used bisphosphonate, zoledronic acid (Zometa), in the treatment of metastatic bone disease. These results follow earlier data from the same study which demonstrated that oral Bondronat is as effective as i.v. zoledronic acid at suppressing bone turnover markers, a surrogate measure of clinical efficacy.

01-03-2006, 02:30 PM	#1
Unregistered Guest Posts: n/a	Oral Bondronat Shows Equal Efficacy and Superior Tolerability with Zometa Bondronat was the subject of an article in a UK paper (Daily Express 3rd Jan 05 page 35), with positive comment from a sufferer with bone mets. Bondronat is being trailed against radiation in the UK by Cancer Research UK, and there is apparently information on their web site info@cancer.org.uk I apologise if this has been posted before. I attach some links from a google search. RB http://qualitycounts.com/drugs/chemo...andronate.html http://www.docguide.com/news/content...25703D0053DBE0 http://www.roche.com/med-cor-2003-07-28 http://www.docguide.com/news/content...2570AB00688815 ABSTRACT Oral Bondronat Shows Equal Efficacy and Superior Tolerability in First Head-to-Head Comparison with Zometa for Treatment of Metastatic Bone Disease in Cancer Patients BASEL, SWITZERLAND -- October 31, 2005 -- Data announced today at the European Cancer Conference (ECCO) in Paris, shows Roche's oral Bondronat(R) (ibandronate) results in fewer adverse events than another commonly used bisphosphonate, zoledronic acid (Zometa), in the treatment of metastatic bone disease. These results follow earlier data from the same study which demonstrated that oral Bondronat is as effective as i.v. zoledronic acid at suppressing bone turnover markers, a surrogate measure of clinical efficacy.